Table of Contents
2003 Annual Shareholder’s Meeting
Agenda 2003 Annual Shareholder’s Meeting
2003 Business Meeting
2003 Results and Future Goals
Forward-Looking Statements
FY 2003 Another Record-Breaking Year!
Sales Growth U.S. & International
Impressive Growth In Gross Profit Margin
Two Full Fiscal Years of Increasing Profitability
Nearly $32 Million Of Cash And Cash Equivalents
National Recognition for Possis Performance
Possis improves the lives of the patients we serve.
FY 2004 Off To a Great Start!
2004 First Quarter Results
Over 150,000 Catheters Sold!
Over 1200 AngioJet® Systems Worldwide 95% of the top US coronary labs have the AngioJet System!
BREAKING NEWS!
Possis is the Leader in US Thrombectomy Markets
Success is a marathon.
Targeted Strategies
Fiscal Year 2004 Primary Financial Objectives
Marketing Overview
Prevalence of Vascular Disease
Prevalence of Vascular Disease
Prevalence of Vascular Disease
Percutaneous Intervention – A Proven Therapy
The Interventional “Tool Kit”
Possis’ Growing “Tool Kit”
What is thrombectomy?
Possis’ Growing “Tool Kit”
Possis’ Growing “Tool Kit”
Thrombectomy Market
Embolic Protection Market Opportunity
Future Markets with Embolic Protection
Key Objectives for 2004
Key Objectives for FY2004
#1: Introduce Rapid Exchange
XMI-RX Catheter First to Market
Key Objectives for FY2004
What is Embolization?
What is Embolic Protection? Two Concepts
AngioJet Partnered with Occlusion Balloon
Lab Video
Our Progress
Key Objectives for FY2004
#3: Introduce integrated drug/device therapy
AngioJet Pulse Spray Lab Demo
A Two Step Process
Power-Pulse Technique Status
Key Objectives for FY2004
#4: Complete Heart Attack Trial
Key Objectives for FY2004
#5: Strategic Investments in Long Term Opportunities
The Other Half of the Story
Visit us at www.possis.com
|